About Sophia Genetics
Sophia Genetics is a publicly listed company based in Rolle (Switzerland) founded in 2011 by Lars Steinmetz, Pierre Hutter, and Jurgi Camblong. AI-based bioinformatics platform for genomic data analysis is provided. Sophia Genetics has raised $248.81 million across 8 funding rounds from investors including Credit Suisse, Hitachi and Eurazeo. The company has 423 employees. Sophia Genetics has completed 1 acquisition, including Interactive biosoftware. Its chief executive, as recorded, is Jurgi Camblong. Its website sophiagenetics.com draws about 39 thousand monthly visits. Sophia Genetics offers products and services including SOPHiA DDMâ„¢, SOPHiA DDMâ„¢ for Genomics, and SOPHiA DDMâ„¢ for Radiomics. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations.
Company details
Provider of an AI-based bioinformatics platform for genomic analysis. The platform uses machine learning algorithms to process and analyze genomic data from patient DNA sequence data generated from the NGS platform. The company also validates genetic tests and caters to hospitals and laboratories. The platform provides insights into disease diagnosis and precision medicine. The companys products like Radiomics assist with precision medicine diagnosis and medical imaging for oncology disease detection. Another product of the company Sophia DDM has features for data organization, drug development, and domain modeling.
- Headquarters Rolle, Switzerland
- Employees 423
- Founders Lars Steinmetz, Pierre Hutter, Jurgi Camblong
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website sophiagenetics.com
- Social LinkedIn X Facebook Instagram YouTube
- Legal Name Sophia Genetics Sa
- Annual Revenue$77.27 M (USD)18.56as on Dec 31, 2025
- Net Profit-$79 M (USD)-26.41as on Dec 31, 2025
- EBITDA-$61.4 M (USD)-4.27as on Dec 31, 2025
- Total Equity Funding$248.81M (USD)
in 8 rounds
- Latest Funding Round$110M (USD), Series F
Oct 2020
- InvestorsCredit Suisse
& 16 more
- Employee Count423
- Investments & Acquisitions
Products & Services of Sophia Genetics
Sophia Genetics offers a comprehensive portfolio of products and services, including SOPHiA DDM™, SOPHiA DDM™ for Genomics, and SOPHiA DDM™ for Radiomics.
AI-driven platform for analyzing genomic and health data
Tool for oncology and inherited disorder insights
Platform for insights from radiology images
Funding Insights of Sophia Genetics
Sophia Genetics has successfully raised a total of $248.81M across 8 strategic funding rounds. The most recent funding activity was a Series F round of $110 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $248.81M
- Total Rounds 8
- Last Round Series F — $110M
- First Round $2.82M
(Apr 2013)
- Investors Count 17
All 8 funding rounds of Sophia Genetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | $110M | Series F | – | aMoon, Hitachi | |
| Jan 2019 | $77M | Series E | – | Generation Investment Management | |
| Dec 2018 | Grant | – | – | ||
| Oct 2018 | Series D | – | Microsoft Accelerator | – | |
| Sep 2017 | $30M | Series D | – | Balderton Capital | |
| Dec 2015 | $15.24M | Series C | – | Alychlo | – |
| Jul 2014 | $13.75M | Series B | – | Invoke Capital, Endeavour Vision | – |
| Apr 2013 | $2.82M | Series A | – | – | – |
17 investors in total: 17 institutional.
Investors in Sophia Genetics
Sophia Genetics has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Credit Suisse, Hitachi and Eurazeo.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in healthcare are focused on by aMoon. | amoon.fund | |||
Investments are made by Swisscom Ventures, backed by Swisscom AG. | ventures.swisscom.com | Ittigen, Switzerland | ||
Endeavour Vision is focused on transformative healthcare technology investments. | endeavourvision.com | Geneva, Switzerland | ||
Private equity firm focused on sustainable investments | generationim.com | London, United Kingdom | ||
Private equity and debt investments are managed across multiple sectors. | 1969 | eurazeo.com | Paris, France | |
Alychlo is engaged in investment activities supporting entrepreneurial dreams. | alychlo.com | Merelbeke, Belgium | ||
Investments are made in beauty, technology, and luxury hospitality sectors. | 2018 | famillec-participations.com | Paris, France | |
ACE Ventures is engaged in venture capital investments globally. | aceventures.vc | Geneva, Switzerland | ||
Equity investments are provided to low and middle market companies. | 1997 | idinvest.com | Paris, France | |
Multistage venture capital investments are focused on technology sectors. | 2000 | balderton.com | London, United Kingdom |
Investor details for Sophia Genetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sophia Genetics
196 people are tracked at Sophia Genetics (60 in leadership, 7 in board & advisors, 129 in team); the tracked headcount is 423.
| Name | Role | Group |
|---|---|---|
Lars Steinmetz | Co-Founder | Leadership |
Pierre Hutter | Co-Founder | Leadership |
Jurgi Camblong | Co-Founder & CEO | Leadership |
Zhenyu Xu | SVP & Chief Scientific Officer | Leadership |
Bram Goorden | SVP & COO | Leadership |
Valeria Sero Ph.D. | Senior Director, Biopharma Business Operations | Leadership |
Philippe Menu | SVP & Chief Medical Officer | Leadership |
Marion Brayer | Senior Director Clinical Operations | Leadership |
Ross Muken | SVP & CFO | Leadership |
Tamara Maas | Head Of Bioinformatics Services, Vice President | Leadership |
Sophie Chevallier | Global Head Of Legal | Leadership |
Kevin Puylaert | VP of Business Development | Leadership |
Rose Lowe | Accounting Manager & Payroll Manager / Treasury And Tax Manager / Treasury & Tax Director | Leadership |
Eric Maillotte | Head Of Supply Chain And Operations | Leadership |
Katherine B. | Head Of Investor Relations | Leadership |
Gerbrand van Bokhorst | Head Corporate Securities Law | Leadership |
Jonathan Vargas | Fp&a Director | Leadership |
Adrian Willig | Director Genomic Research | Leadership |
Alexandru Bello | Senior Director, Head Of Technology Infrastructure | Leadership |
Yves Serroen | Biopharma Business Development Director | Leadership |
176 more people are available in the full profile.
Complete people profiles for Sophia Genetics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sophia Genetics
Sophia Genetics is a publicly listed company on the NASDAQ with ticker symbol SOPH in USA, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Jul 2021
- Listed onNASDAQ: SOPH
- Listed entitySOPHiA GENETICS SA
- Exchange sectorTechnology services
- ISINCH1125843347
- Share price$7.09 (-1.8% on the day) · 2026-10-13
- Market capitalisation$603.6M
- EPS (diluted, trailing year)$-1.15
- Volume (last session)271,218
Financials of Sophia Genetics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $77.3M | -$79.0M | -$61.4M |
| 2024 | $65.2M | -$62.5M | -$58.9M |
| 2023 | $62.4M | -$79.0M | -$68.6M |
| 2022 | $47.6M | -$87.5M | -$83.9M |
| 2021 | $40.5M | -$73.7M | -$69.6M |
Detailed financial statements for Sophia Genetics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sophia Genetics
Sophia Genetics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Interactive biosoftware.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Software tools for next-generation sequencing data analysis are provided. | interactive-biosoftware.com | Rouen, France | 2007 | Jun 2018 | •••• |
Complete acquisition details for Sophia Genetics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Sophia Genetics
5 dated milestones of Sophia Genetics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Sophia Genetics is founded.
- Funding First funding round of $2.8M.
- Acquisition Acquires Interactive biosoftware.
- Funding Latest funding round, Series F, of $110.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Sophia Genetics
The website of Sophia Genetics (sophiagenetics.com) receives about 39.4K visits a month and ranks #679,201 among all websites worldwide, #756 in Biotechnology and Pharmaceuticals.
- Monthly visits39.4K
▼ 14.8% vs previous month
- Unique visitors19.5K
per month
- Global rank#679,201
among all websites
- Category rank#756
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit2.1
- Average visit36 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with Sophia Genetics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ultimagenomics.com | 100% | 12.9K | #2,282,855 | View details | |
hgvs-nomenclature.org | hgvs-nomenclature.org | 73% | #971,046 | – | |
americanhs.org | americanhs.org | 66% | – | ||
| goodstartgenetics.com | 65% | View details | |||
atlasgenetics.com | atlasgenetics.com | 64% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Sophia Genetics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sophia Genetics
Complete news archive for Sophia Genetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sophia Genetics
Sophia Genetics was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Sophia Genetics is headquartered in Rolle, Switzerland. It is registered at Rolle, Vaud, Switzerland.
Jurgi Camblong is the CEO of Sophia Genetics, as recorded in our data. They have also founded this company.
Sophia Genetics is a funded company, having raised a total of $248.81M across 8 funding rounds to date. The company's 1st funding round was a Series A of $2.82M, raised on Apr 2013.
Sophia Genetics has 423 employees.
Annual revenue of Sophia Genetics is $77.27M as on Dec 31, 2025.
Provider of an AI-based bioinformatics platform for genomic analysis. The platform uses machine learning algorithms to process and analyze genomic data from patient DNA sequence data generated from the NGS platform. The company also validates genetic tests and caters to hospitals and laboratories. The platform provides insights into disease diagnosis and precision medicine. The companys products like Radiomics assist with precision medicine diagnosis and medical imaging for oncology disease detection. Another product of the company Sophia DDM has features for data organization, drug development, and domain modeling.
Sophia Genetics offers SOPHiA DDMâ„¢, SOPHiA DDMâ„¢ for Genomics, and SOPHiA DDMâ„¢ for Radiomics.
Yes, Sophia Genetics is publicly traded on NASDAQ under the ticker symbol SOPH.
Sophia Genetics has made 1 acquisition, including Interactive biosoftware.
Sophia Genetics has 17 investors. Key investors include Credit Suisse, Hitachi, Eurazeo, Idinvest Partners, and Balderton Capital.